Sealantium Medical

Executive Summary

Sealantium Medical Ltd. is an Israeli biosurgery company pioneering next-generation tissue sealants and hemostatic agents to address critical unmet needs in surgical bleeding control. Its flagship product, sFilm-FS™, uniquely combines a biodegradable polymeric film with fibrin sealant to achieve rapid hemostasis and tissue sealing in under two minutes. The dual-action platform is designed for both open and minimally invasive surgeries, with an initial focus on high-risk procedures such as liver resections where effective hemostasis is challenging. Existing solutions, including topical hemostats and fibrin glues, often suffer from insufficient adhesion, long preparation times, or inadequate sealing in active bleeding environments. sFilm-FS aims to overcome these limitations through its pre-applied film design that provides immediate, robust sealing without the need for mixing or curing, potentially reducing operative time and improving patient outcomes. The company is currently in Phase 2 clinical development, building on promising preclinical data demonstrating superior sealing strength and safety. The global surgical hemostasis market exceeds $3 billion annually, driven by the rise in minimally invasive surgery and the aging population. If clinical trials confirm efficacy and safety, sFilm-FS could capture significant market share by offering a differentiated, easy-to-use product. Sealantium has a strong intellectual property portfolio and an experienced management team with deep expertise in medical device development. Key upcoming milestones include completion of patient enrollment and interim data readouts, which will be critical for validating the technology and attracting potential strategic partners. The company is well-positioned to become a leader in the biosurgery space, with the potential to expand its platform into additional surgical indications.

Upcoming Catalysts (preview)

• Q3 2026Completion of Phase 2 Clinical Trial Enrollment80% success
• Q4 2026Presentation of Interim Phase 2 Data at a Major Surgical Conference70% success